Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of pseudotumor cerebri associated with iron deficiency anemia due to colon cancer is reported in a 37-year-old woman. Her initial symptoms were vomiting and severe headache. On physical examination, no lymph nodes and abdominal mass were palpable but marked anemia was noted in her skin and conjunctiva . Neurological examination revealed papilledema in her both eyes and stiff neck. There was no abnormal findings on CT scan on admission. Spinal puncture revealed CSF pressure as high as 620 mmH2O with normal cells, protein, sugar and chloride levels. Hematological examination revealed iron deficiency anemia and thrombocytosis. Angiography at third day revealed no sinus occlusion, but retention of contrast media was seen on the cortical vein of parietal lobe and right transverse sinus. Brain scintigram at sixth day revealed mild accumulation in left parietal lobe, so small venous infarction was suggested. There were two circumscribed stenotic lesions of right ascending colon in the barium enema, and right hemicolectomy was achieved. The pathological diagnosis was adenocarcinoma. The symptoms of pseudotumor cerebri was completely disappeared soon after the surgery together with resolution of anemia. She lives with no deficits now 1 year 3 months after surgery. In conclusion much attention is necessary to a patient of pseudotumor cerebri with iron deficiency anemia for the presence of cancer, because not only this central nervous system lesion is reversible and curable but also the cancer itself may be curable by surgery.
 ...
PMID:[A case of pseudotumor cerebri associated with colon cancer]. 280 39

A 54-year-old man initially complained of frontal headache, right ear pain and tinnitus in May, 1985. This was followed by right facial palsy and hearing loss, and he was admitted to our hospital. Physical findings revealed right trigeminal nerve disturbance, left facial nerve palsy and bulbar palsy. The spinal fluid showed pleocytosis, increased protein, decreased glucose, markedly increased carcinoembryonic antigen and adenocarcinoma cells. Gastric carcinoma was revealed by an upper GI series. He was treated with chemotherapy. However, he die in August, 1985. Nodular metastases were discovered at the right internal acoustic meatus and other areas. Microscopically, signet-ring cell carcinoma had diffusely infiltrated at the subarachnoid space.
 ...
PMID:[An autopsy case of meningeal carcinomatosis with vestibulocochlear nerve disturbance as the first manifestation]. 302 29

Histologically-verified triple cancers that include a malignant brain tumor are rare. According to the Japan Autopsy Annuals, only 8 cases since 1958 have been so far documented. A case combining a malignant melanoma, a medulloblastoma, and a thyroid cancer is herein presented, along with a review of the literature. In March, 1983, a 27-year-old female who, 7 years prior to admission, had had malignant melanoma on the right hand removed, complained of headaches and vertigo. A CT scan revealed a right cerebellar mass lesions, which subsequently proved to medulloblastoma. Three years later, a struma was found and subtotal thyroidectomy revealed a papillary adenocarcinoma.
 ...
PMID:[A histologically-verified triple cancer--report of a rare case involving a primary brain tumor]. 304 37

Tumor-to-tumor metastasis is a rare occurrence. Fewer than 100 cases have been reported, many being metastases from carcinomas to benign intracranial neoplasms, most often meningiomas. A case is presented of carcinoma metastatic to a glioma. The patient, who presented for evaluation of bifrontal headache, was found on computerized tomography to have a partially calcified right frontal mass. Craniotomy revealed an oligodendroglioma containing foci of adenocarcinoma. Further work-up disclosed an infiltrative ductal adenocarcinoma of the breast. It has been suggested that tumors of the central nervous system may provide a fertile substrate or an immunological "haven" for metastases.
 ...
PMID:Metastases of central nervous system neoplasms. Case report. 328 41

The toxic effects of protein A (Prosorba, IMRE Corporation, Seattle, WA) treatments given as part of an on-line plasmapheresis or off-line procedure were determined in a Phase I Study. Patients were randomized and treated 12 times either once per week or three times per week with a Prosorba column containing 50 or 200 mg protein A. Treated plasma volumes varied from 150 ml off-line to 2000 ml on-line. Seven patients having advanced metastatic breast adenocarcinoma patients were evaluated. All had advanced progressive disease that was resistant to chemotherapy and/or radiation therapy. Greater than 50% regression of measurable tumor volume occurred in four of seven patients; an additional patient responded with 33.5% regression. Two patients with only bony metastases demonstrated stable disease for a 60-day period. Side effects resulting from protein A treatments included transient fever, chills, rigors, and infrequently nausea, vomiting, diarrhea, episodic hyper and/or hypotension, bronchospasm, venospasm, headache, joint and tumor pain. Mild to moderate reactions were seen in all patients regardless of clinical response, but abated spontaneously or were controlled with pretreatment and/or post treatment with antipyretics and/or antihistaminics. The side effects decreased notably during the course of the week with the more intense reaction occurring during the first treatment of the week. Side effects occurred regardless of column size or volume of plasma treated. In the course of 12 treatments, anemia requiring transfusion developed in two of seven patients. Significant tumor regression was obtained in this group of patients with advanced disease. In light of the mild to moderate side effects and tumor regression in five of seven of the patients treated, protein A treatment merits further evaluation to determine the effectiveness of this treatment in breast adenocarcinoma.
 ...
PMID:Toxicity following protein A treatment of metastatic breast adenocarcinoma. 334 17

Intracerebral hemorrhage from a brain tumor can mask the cause of bleeding, confuse the diagnosis, and affect the treatment and prognosis. This type of hemorrhage is generally regarded as a rapidly progressive, fulminating disease, sudden in onset, with the outcome being death or profound neurological deficits. Such hemorrhages are demonstrated by CT scan as intracerebral high density areas. Intracerebral hematomas producing chronic neurological disability and chronic intracerebral hematomas are rarely reported. We experienced a case of chronic intracerebral hematoma due to metastatic brain tumor. The patient was a 60-year-old female, and the initial symptoms were mild headache followed by right homonymous hemianopsia. The intracranial lesion was demonstrated by CT scan as an oval-shaped low density area (3 X 4.5 cm) with a ring enhancement in the left occipital lobe. MRI showed marked high intensity by short SE and long SE in the left occipital lobe. A left occipital craniotomy was performed. No tumor could be seen macroscopically except for an old encapsulated hematoma. Aspiration of the liquid hematoma and biopsy of the wall of the hematoma were done. A histological examination revealed an adenocarcinoma. Spontaneous bleeding from brain tumors was reviewed, and diagnostic problems were discussed.
 ...
PMID:[Chronic encapsulated intracerebral hematoma due to metastatic brain tumor: a case report]. 337 50

Antineoplaston A3 is an oxidated mixture of small peptides and amino acid derivatives isolated from human urine which have shown antineoplastic activity in tissue culture and low toxicity in mice. Twenty-four patients diagnosed with 25 cases of neoplastic diseases were involved in the studies. The patients' diagnoses included: adenocarcinoma of the prostate, stage IV (7 cases); adenocarcinoma of the breast, stage IV (3); adenocarcinoma of the colon and rectum, stage IV (3); adenocarcinoma of the colon, status post resection (1); adenocarcinoma of the lung, stage III (2); squamous cell carcinoma of the lung, stage III (2); adenocarcinoma of the pancreas, stages II and IV (2); and single cases of adenocarcinoma of the kidney, stage IV; malignant fibrohistiocytoma, stage IV; glioblastoma multiforme, stage IV; basal cell epithelioma; and transitional cell carcinoma of the bladder, grade II. Only patients who had over six weeks' anticipated survival and who continued the treatment for over six weeks were eligible. In 23 patients, Antineoplaston A3 was administered in divided doses daily i.v. through a subclavian vein catheter. In one patient, the injections were given i.m. The length of treatment was from 44 to 478 days and the highest dosage was 76 mg/kg/24 h. Side-effects associated with treatment included febrile reaction (4 patients), vertigo (2), headache (2), flushing of the face, nausea and tachycardia (1 each). Adverse reactions were mild and occurred only once during the entire course of treatment. Desirable side-effects included increase of platelet count, increase of white blood cell count and increase of reticulocyte count. At the end of the study, there were 5 cases of complete remission, 5 of partial remission, nine of stable disease and six of increasing disease. The patients who obtained complete remission were diagnosed with cancers of the bladder, prostate, colon, and basal cell epithelioma. In view of its very limited toxicity and the interesting responses obtained, Antineoplaston A3 was submitted for Phase II clinical trials to establish its usefulness in cancer treatment.
 ...
PMID:Phase I clinical studies of antineoplaston A3 injections. 356 12

Antineoplaston A10 injections were administered to 18 patients diagnosed with 19 types of neoplastic disease. The patients' diagnoses included: adenocarcinoma of the rectum and colon, Stage IV (8 cases); adenocarcinoma of the pancreas (4 cases); adenocarcinoma of the breast, Stage IV (3 cases) and single cases of adenocarcinoma of the lungs, Stage III; adenocarcinoma of the stomach, Stage IV; chondrosarcoma of the nose and right maxillary sinus; and carcinoid. The treatment was administered from 52 to 640 days. The highest dosage taken was 2210.5 mg/kg/24 h. Most of the patients were taking from 206.9 to 387.1 mg/kg/24 h. The treatment was associated with minimal side-effects including febrile reactions, muscle and joint pain, muscle contraction in the throat, abdominal pain of short duration and single incidences of nausea, dizziness and headache. Desirable side-effects included increase of platelet count and white blood cell count. Objective response to the treatment was noticed in 8 patients including one patient diagnosed with intraductal carcinoma of the breast, Stage IV, 2 patients with adenocarcinoma of the sigmoid, Stage IV, 1 patient with adenocarcinoma of the rectum, Stage IV, 2 patients with adenocarcinoma of the pancreas, 1 patient with adenocarcinoma of the lung, Stage III, and 1 chondrosarcoma.
 ...
PMID:Toxicology studies on antineoplaston A10 injections in cancer patients. 374 80

A 55 year-old man complained of headaches, dizziness and vomiting. Neurological examination only showed a cerebellar syndrome. CT scan revealed two hyperdense round areas in the right frontal lobe and cerebellar vermis consistent with metastases and a lung carcinoma was diagnosed. Two months later he presented with typical right hemichorea. A second CT scan showed another hypodense lesion with slight contrast enhancement in the left subthalamic region. He died 6 months after clinical onset. Post mortem examination showed an adenocarcinoma of the right lung with liver metastases. Neuropathological examination revealed four intraparenchymatous metastases one of which involved the left subthalamic nucleus. Hemichorea secondary to metastatic neoplasm of the corpus Luysii is uncommon; only 6 cases have been reported previously; five of them had a post mortem examination of the brain. In three cases a CT scan was available and had demonstrated the site and nature of the lesion.
 ...
PMID:[Hemiballismus and metastasis to the Luys' body. An anatomo-clinical case]. 378 60

A 66-year-old woman with a subacute onset of mild dementia and headaches was discovered to have multiple large, hyperdense lesions on cranial CT scan. Biopsy showed poorly differentiated adenocarcinoma with necrosis and dystrophic calcification, which represented an unusual initial manifestation of metastatic breast carcinoma after a seven-year disease-free period. Neurologic symptoms improved with tamoxifen therapy.
 ...
PMID:Calcified intracranial metastases from breast carcinoma with a therapeutic response to tamoxifen therapy. 394 60


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>